OBJECTIVE: To compare efficacy of Omega-3/6 fatty acids (Equazen eye q™) with methylphenidate (MPH) and combined MPH + Omega-3/6 in children with ADHD. METHOD: Participants ( N = 90) were randomized to Omega-3/6, long-acting MPH, or combination for 12 months. ADHD symptoms were assessed using the ADHD Rating Scale and Clinical Global Impressions-Severity (CGI-S) scale. RESULTS:ADHD symptoms decreased in all treatment arms. Although significant differences favoring Omega + MPH over Omega-3/6 alone were found for ADHD Total and Hyperactivity-Impulsivity subscales, results on the Inattention subscale were similar. CGI-S scores decreased slowly and consistently with Omega-3/6, compared with a rapid decrease and subsequent slight increase in the MPH-containing arms. Adverse events were numerically less frequent with Omega-3/6 or MPH + Omega-3/6 than MPH alone. CONCLUSION: The tested combination of Omega-3/6 fatty acids had similar effects to MPH, whereas the MPH + Omega combination appeared to have some tolerability benefits over MPH.
RCT Entities:
OBJECTIVE: To compare efficacy of Omega-3/6 fatty acids (Equazen eye q™) with methylphenidate (MPH) and combined MPH + Omega-3/6 in children with ADHD. METHOD:Participants ( N = 90) were randomized to Omega-3/6, long-acting MPH, or combination for 12 months. ADHD symptoms were assessed using the ADHD Rating Scale and Clinical Global Impressions-Severity (CGI-S) scale. RESULTS:ADHD symptoms decreased in all treatment arms. Although significant differences favoring Omega + MPH over Omega-3/6 alone were found for ADHD Total and Hyperactivity-Impulsivity subscales, results on the Inattention subscale were similar. CGI-S scores decreased slowly and consistently with Omega-3/6, compared with a rapid decrease and subsequent slight increase in the MPH-containing arms. Adverse events were numerically less frequent with Omega-3/6 or MPH + Omega-3/6 than MPH alone. CONCLUSION: The tested combination of Omega-3/6 fatty acids had similar effects to MPH, whereas the MPH + Omega combination appeared to have some tolerability benefits over MPH.
Authors: Toshiko Matsudaira; Rachel V Gow; Joanna Kelly; Caroline Murphy; Laura Potts; Alexander Sumich; Kebreab Ghebremeskel; Michael A Crawford; Eric Taylor Journal: J Child Adolesc Psychopharmacol Date: 2015-12 Impact factor: 2.576
Authors: Dienke J Bos; Bob Oranje; E Sanne Veerhoek; Rosanne M Van Diepen; Juliette Mh Weusten; Hans Demmelmair; Berthold Koletzko; Monique Gm de Sain-van der Velden; Ans Eilander; Marco Hoeksma; Sarah Durston Journal: Neuropsychopharmacology Date: 2015-03-19 Impact factor: 7.853